Calmodulin binding to the C-terminus of the small-conductance Ca2+-activated K+ channel hSK1 is affected by alternative splicing.
We identified three splice variants of hSK1 whose C-terminal structures are determined by the independent deletion of two contiguous nucleotide sequences. The upstream sequence extends 25 bases in length, is initiated by a donor splice site within exon 8, and terminates at the end of the exon. The downstream sequence consists of nine bases that compose exon 9. When the upstream sequence (hSK1(-)(25b)) or both sequences (hSK1(-)(34b)) are deleted, truncated proteins are encoded in which the terminal 118 amino acids are absent. The binding of calmodulin to these variants is diminished, particularly in the absence of Ca2+ ions. The first 20 amino acids of the segment deleted from hSK1(-)(25b) and hSK1(-)(34b) contain a 1-8-14 Ca2+ calmodulin binding motif, and synthetic oligopeptides based on this region bind calmodulin better in the presence than absence of Ca2+ ions. When the downstream sequence (hSK1(-)(9b)) alone is deleted, only the three amino acids A452, Q453, and K454 are removed, and calmodulin binding is not reduced. On the basis of the relative abundance of mRNA encoding each of the four isoforms, the full-length variant appears to account for most hSK1 in the human hippocampus, while hSK1(-)(34b) predominates in reticulocytes, and hSK1(-)(9b) is especially abundant in human erythroleukemia cells in culture. We conclude that the binding of calmodulin by hSK1 can be modulated through alternative splicing.
Department of Medicine, Baylor College of Medicine, and Research Department, VA Medical Center, Houston, Texas 77030, USA.
B M
BM
Zhang
V
V
Kohli
R
R
Adachi
J A
JA
López
M M
MM
Udden
R
R
Sullivan
D017398:Alternative Splicing / Q000235:genetics*; D000595:Amino Acid Sequence; D002118:Calcium / Q000502:physiology*; D002147:Calmodulin / Q000378:metabolism*; D003001:Cloning, Molecular; D006624:Hippocampus / Q000737:chemistry; D006801:Humans; D008969:Molecular Sequence Data; D009842:Oligopeptides / Q000138:chemical synthesis / Q000235:genetics / Q000378:metabolism; D010446:Peptide Fragments / Q000235:genetics / Q000378:metabolism*; D015221:Potassium Channels / Q000235:genetics* / Q000378:metabolism*; D024681:Potassium Channels, Calcium-Activated; D011485:Protein Binding / Q000235:genetics; D020033:Protein Isoforms / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger / Q000032:analysis; D012334:RNA, Neoplasm / Q000032:analysis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012260:Ribonucleases / Q000235:genetics; D017384:Sequence Deletion; D051640:Small-Conductance Calcium-Activated Potassium Channels; D014407:Tumor Cells, Cultured
D002147:Calmodulin; C496894:KCNN1 protein, human; D009842:Oligopeptides; D010446:Peptide Fragments; D015221:Potassium Channels; D024681:Potassium Channels, Calcium-Activated; D020033:Protein Isoforms; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D051640:Small-Conductance Calcium-Activated Potassium Channels; D012260:Ribonucleases; D002118:Calcium